Resonetics® Acquires Eden Holdings, Adding Injection Molding to its Capabilities

Rhea-AI Summary

Resonetics (NYSE:CG) has acquired Eden Holdings, comprising Eden Manufacturing and Eden Tool, to expand its precision manufacturing capabilities in the medical device sector. The acquisition integrates Eden's expertise in micro-molding, insert-molding, and advanced machining and tooling with Resonetics' established metal processing capabilities.

Eden, founded in 2000, specializes in Class 101 production tooling for the MedTech industry and serves high-growth markets including robotic surgery, minimally invasive surgery, electrophysiology, and rapid diagnostics. The strategic acquisition enhances Resonetics' ability to deliver integrated solutions across materials and technologies for complex medical devices.

Positive

• Strategic expansion into precision micro-molding and tooling capabilities
• Access to high-growth medical device markets including robotic surgery and diagnostics
• Enhanced integrated solutions offering across materials and technologies
• Complementary addition to existing metal processing expertise

Negative

• Integration challenges may arise from combining different manufacturing processes
• Potential operational complexity in managing expanded capabilities

Insights

M&A Analyst

Resonetics expands capabilities with Eden acquisition, strengthening its integrated MedTech manufacturing solutions portfolio.

Resonetics' acquisition of Eden Holdings represents a strategic expansion of its manufacturing capabilities in the medical device sector. This transaction adds critical polymer processing expertise - specifically precision micro-molding, insert molding, and advanced tooling - to complement Resonetics' existing metal processing strengths.

The acquisition creates significant technology synergies by combining Resonetics' metal manufacturing capabilities with Eden's polymer expertise. This enables Resonetics to offer more comprehensive solutions across multiple materials and manufacturing processes - a key competitive advantage when serving medical device OEMs who increasingly seek integrated supply chain partners.

Eden's specialization in Class 101 production tooling (the highest precision classification for molds) and engineering-driven approach positions Resonetics to better serve high-growth medical segments including robotic surgery, minimally invasive procedures, electrophysiology, and rapid diagnostics. These markets demand extremely precise components with complex geometries where Eden has established expertise.

This transaction follows the medical device industry trend of consolidation among specialized manufacturers, as OEMs prefer working with fewer suppliers who can provide more comprehensive solutions. By expanding its polymer capabilities, Resonetics strengthens its position as a differentiated partner for micro-manufacturing of complex medical components.

Acquisition adds precision micro-molding, insert molding, and advanced machining and tooling to Resonetics' portfolio of precision manufacturing capabilities.

NASHUA, N.H., Sept. 29, 2025 /PRNewswire/ -- Resonetics announced today that it has acquired Eden Holdings (Eden), comprising both Eden Manufacturing and Eden Tool, a precision manufacturer specializing in injection molding and micro machining solutions for critical medical devices. The acquisition adds micro-molding, insert-molding, and advanced machining and tooling, complementing Resonetics' established metal processing capabilities, while also expanding the Swiss machining and EDM machining offerings. These additions enhance Resonetics' portfolio of specialized MedTech capabilities to serve high-growth markets including among others robotic surgery, minimally invasive surgery, electrophysiology, and rapid diagnostics.

Founded in 2000, Eden has built a strong reputation for its expertise in precision tooling and machining, which evolved into high precision micro and insert molding for critical medical devices. The company also specializes in Class 101 production tooling for the MedTech industry, delivering molds and components that demand uncompromising precision, complex geometries, and exceptional quality. Eden's engineering-driven approach to mold design and manufacturing ensures consistent, reliable solutions that meet the rigorous standards of leading MedTech OEMs.

"With the addition of Eden, we are enhancing our ability to deliver integrated solutions across materials and technologies. Eden's strength in injection molding and precision tooling is a critical addition, bringing valuable new capabilities that complement our metal processing expertise across our entire portfolio and enable us to deliver a more integrated offering to our customers," said Kevin Kelly, CEO of Resonetics.

"Joining Resonetics gives Eden access to greater resources and a global platform to better serve our customers. We're excited to combine our precision tooling, insert molding, and micro-molding expertise with Resonetics' advanced technologies to provide even more value to the medical device industry," said David Tomic, President of Eden.

The acquisition of Eden expands Resonetics' polymer capabilities and adds another key area of expertise, reinforcing its position as a differentiated partner delivering micro manufacturing solutions for complex medical devices.

About Resonetics
Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs^® and AGILE Product Development^® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 17 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy^™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in over 280 companies, and the firm currently manages $45 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

View original content to download multimedia:https://www.prnewswire.com/news-releases/resonetics-acquires-eden-holdings-adding-injection-molding-to-its-capabilities-302568600.html

SOURCE Resonetics, LLC

FAQ

What companies did Resonetics (NYSE:CG) acquire in September 2025?

Resonetics acquired Eden Holdings, which includes Eden Manufacturing and Eden Tool, companies specializing in injection molding and micro machining solutions for medical devices.

What new capabilities does the Eden acquisition add to Resonetics?

The acquisition adds micro-molding, insert-molding, advanced machining and tooling capabilities, while expanding Swiss machining and EDM machining offerings.

What markets will Resonetics serve with Eden's capabilities?

The combined company will serve high-growth markets including robotic surgery, minimally invasive surgery, electrophysiology, and rapid diagnostics.

When was Eden Holdings founded and what is their specialty?

Eden was founded in 2000 and specializes in precision tooling, machining, and Class 101 production tooling for the MedTech industry.

Who will lead Eden after the Resonetics acquisition?

David Tomic, the President of Eden, will continue with the company, while the combined entity will be led by Kevin Kelly, CEO of Resonetics.